

Supporting Information

Enantiomeric atropisomers inhibit HCV polymerase and/or HIV matrix: Characterizing hindered bond rotations and target selectivity

Steven R. LaPlante,* Pat Forgione, Colette Boucher, René Coulombe, James Gillard,
Oliver Hucke, Araz Jakalian, Marc-André Joly, George Kukolj, Christopher Lemke,
Robert McCollum, Steve Titolo, Pierre L. Beaulieu, Timothy Stammers

Table of Contents:

Appendix 1: Information are provided for the HIV matrix assay along with NMR data.

Appendix 2: Compound characterizations.

Appendix 1: Information are provided for the assay and NMR of HIV matrix.




Figure S1. (A) ^{15}N TROSY spectrum of apo matrix along with the resonance assignments. (B) This data can be regarded as structural probes as displayed on the X-ray structure.




Figure S2. Addition PIP2 substrate shows the peaks that change positions due to binding. K_D determinations for PIP2 binding employed the ratios of ligand to matrix shown in Figure S2. The shift changes (Hz) versus compound concentration were fit using Graphpad (one-site binding), and a K_D of $\sim 40 \mu\text{M}$ was determined.





Figure S3. Shown are information regarding the constructs and functions.


Appendix 2: Compound Characterization (continuation from Materials and Methods)

Compound syntheses. Synthesis of compounds **1** and **2** are described in **WO2009/018656**.

The synthesis of Compound **3** is described below.




The synthesis of Compound **4** is described below.



Reagents and conditions: i) NaH / DMF / RT ii) LiOH / water / MeOH / RT

The synthesis of compounds **5** to **8** are described in **WO2007/87717**.


The synthesis of Compound **9** is described below.



Reagents and conditions: i) DMSO / K_2CO_3 / $75^\circ C$ ii) $NHCO_3$ / Boc_2O / THF / RT iii) 10% Pd/C / MeOH / EtOAc / RT iv) 2-methoxypropene / HOAc / DCM / $NaBH(OAc)_3$ / RT v) **Acid Chloride A** / pyridine / DMAP / $60^\circ C$ vi) DCM / TFA / RT vii) *p*-methoxybenzoic acid / TEA / DMSO / TBTU / RT viii) NaOH / water / $50^\circ C$.


Compound 1

White lyophilized solid. Purity by HPLC > 99%. MS found MH⁺ 578.2 Da. HRMS calculated 578.2385, found 578.2388.



Compound 2


White lyophilized solid. Purity by HPLC 100%. MS found MH⁺ 608.3 Da. HRMS calculated 5608.2491, found 608.2516.




Compound 3

Off-white solid. Purity by HPLC >95%. HRMS calculated 564.2592, found 564.2590.


Example of how all compounds were characterized by NMR




Example of how all compounds were characterized by NMR




Example of how all compounds were characterized by NMR



Example of how all compounds were characterized by NMR




^1H - ^{13}C HSQC



Compound 3

Compound 4



White lyophilized solid. Purity by HPLC 100%. MS found MH⁺ 636.3 Da. HRMS calculated 636.2680, found 636.2677.



Compound 5

Beige solid. Purity by HPLC >99.9%. MS found MH⁺ 422.1 Da. HRMS calculated 422.1574, found 422.1592.


Frequency (MHz) 400.13




Compound 6

Off-white lyophilized powder. Purity by HPLC >99.9%. MS found MH⁺ 436.1 Da. HRMS calculated 436.1730, found 436.1746.

Frequency (MHz) 400.13




¹H NMR (400 MHz, DMSO-d₆) δ 7.79-7.88 (m, 1H), 7.69-7.77 (m, 1H), 7.38-7.48 (m, 3H), 7.26-7.35 (m, 1H), 7.14-7.26 (m, 1H), 3.04 (s, 3H), 1.82-1.93 (m, 1H), 1.66-1.81 (m, 1H), 1.17-1.64 (m, 7H), 0.96-1.08 (m, 1H), 0.71-0.91 (m, 3H), 0.47-0.69 (m, 2H)




Compound 7

Off-white lyophilized powder. Purity by HPLC >99.9%. MS found MH⁺ 464.1 Da. HRMS calculated 464.2043, found 464.2058.



Compound 8

Off-white lyophilized powder. Purity by HPLC >99.9%. MS found MH⁺ 519.2 Da. HRMS calculated 519.2465, found 519.2477.



Compound 9

White solid. Purity by HPLC 99%. MS found $M+H = 545.2$ Da. HRMS calculated 545.2646, found 545.2670.

